Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TherVacB therapeutic hepatitis B vaccine trial
2023-507623-36-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label trial of hepatitis B vaccine recombinant in Chronic Hepatitis B (CHB) (3 arms), sponsored by LMU Klinikum. Primary endpoints: Unsolicited adverse events, Serious adverse events and 5 more. Planned start May 2025; status: authorised.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-507623-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507623-36-00.